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Pancreatic carcinoma has a dismal prognosis as it often presents as locally advanced or metastatic. We have found that exposure
to adamantyl-substituted retinoid-related (ARR) compounds 3-Cl-AHPC and AHP3 resulted in growth inhibition and apoptosis
induction in PANC-1, Capan-2, and MiaPaCa-2 pancreatic cancer cell lines. In addition, AHP3 and 3-Cl-AHPC inhibited growth
and induced apoptosis in spheres derived from the CD44+/CD24+ (CD133+/EpCAM+) stem-like cell population isolated from
the pancreatic cancer cell lines. 3-Cl-AHPC-induced apoptosis was preceded by decreasing expression of IGF-1R, cyclin D1, β-
catenin, and activated Notch-1 in the pancreatic cancer cell lines. Decreased IGF-1R expression inhibited PANC-1 proliferation,
enhanced3-Cl-AHPC-mediatedapoptosis,andsigniﬁcantlydecreasedsphereformation.3-Cl-AHPCinhibitedtheWnt/β-catenin
pathway as indicated by decreased β-catenin nuclear localization and inhibited Wnt/β-catenin activation of transcription factor
TCF/LEF. Knockdown of β-catenin using sh-RNA also induced apoptosis and inhibited growth in pancreatic cancer cells. Thus, 3-
Cl-AHPC and AHP3 induce apoptosis in pancreatic cancer cells and cancer stem-like cells and may serve as an important potential
therapeutic agent in the treatment of pancreatic cancer.
1.Introduction
Pancreatic cancer is the fourth leading cause of cancer
associated mortality. Approximately 50% of the patients
present with locally advanced unresectable disease and
35% with metastatic disease [1]. In those patients who
undergo resection, 75% develop a recurrence and succumb
to metastatic pancreatic cancer [1]. The dismal prognosis of
pancreatic cancer is further accentuated by its poor response
to chemotherapy and to radiation therapy. Although treat-
ment with gemcitabine has resulted in some improvement
in the overall well-being of some of the patients, no
chemotherapeutic regimen has had a signiﬁcant impact on
the survival of patient with metastatic disease with median
survivals in the 4 to 6 month range. Thus the discovery
of new therapeutic agents and approaches to patients with
pancreatic cancer is of paramount importance.
Examination of tumors has resulted in the observation
thatasubpopulationofthetumorcellspossesstheproperties
of stem cells, that is, cells that are capable of undergoing self-
renewal and as well as generating the heterogeneous lineages
of cancer cells that comprise the majority of the tumor [2].
Pancreatic cancer stem cells have been identiﬁed in both
pancreatic carcinoma cell lines as well as pancreatic cancer
tissue obtained from patients [1, 3, 4]. A major emphasis has
now been placed on detecting the speciﬁc pathways that are
required for the proliferation and maintenance of these stem
cells in the hope of developing speciﬁc targeted therapies
resulting in the death of these cells.2 Journal of Oncology
We and others have shown that a unique class of
compounds termed the adamantyl-substituted retinoid-re-
lated molecules (ARRs)(E)-4-[3-(1-adamantyl)-4-hydrox-
yphenyl]-3-chlorocinnamic acid (3-Cl-AHPC) and (E)-3-
{2-[3-(1-adamantyl)-4-hydroxyphenyl]-5-pyrimidinyl}-2-
propenoic acid (AHP3 or BI-2005) inhibits proliferation
and induces apoptosis in vitro and in vivo o fan u m b e ro f
malignantcelltypes[5–9].Inthispaper,wedemonstratethat
the ARRs are not only capable of inhibiting the growth of
pancreaticcancercellsinvitrobutalsoinhibitthegrowthand
induce apoptosis in the pancreatic stem-like cell population.
Exposure to the ARR compounds AHP3 and 3-Cl-AHPC
resulted in the inhibition of stem cell sphere formation
as well as apoptosis induction in the stem-like cells.
Apoptosis induction was preceded by marked inhibition of
IGF-1R, cyclin D1, β-catenin, and Notch-1 expression in
pancreatic cells, but only IGF-1R, cyclin D1, and β-catenin
in the cancer stem-like cells. Decreased IGF-1R expression
enhanced ARR apoptosis induction and inhibited pancreatic
carcinoma growth and sphere formation. β-catenin
knockdown inhibited TCF/LEF transcriptional activity and
downregulated Wnt/β-catenin target genes. The subsequent
enhanced apoptosis and inhibition of growth in pancreatic
cells suggests that the inhibition of Wnt/β-catenin signaling
pathway is important for 3-Cl-AHPC-mediated apoptosis.
2.MaterialsandMethods
2.1. Reagents. 3-Cl-AHPC was synthesized as described [5,
6]. DMEM-F12 medium, fetal bovine serum (FBS), lipofec-
tamine 2000, and Prolong antifade kit were purchased from
Invitrogen (Carlsbad, CA). Antibodies and their sources
were as follows: antibodies for ﬂow cytometry, CD44-
PE, CD24-FITC, anti-EpCAM-PerCP-Cy5.5, and anti-c-Myc
antibody from BD Biosciences (San Jose, CA) and CD44-
APC-Cy7 and CD24-APC from Biolegend (San Diego, CA).
Anti-CD44, anti-IGF-1Rβ, anti-β-catenin, anti-caspase 3,
anti-cleaved caspase-3, and activated anti-cleaved Notch-1
(Val 1744) were from Cell Signaling Technology (Boston,
MA); anti-CD24 and anti-cyclin D1 antibodies from Santa
Cruz Biotechnology (Santa Cruz, CA); CD133-PE and
CD326-FITC (EpCAM) from Miltenyi Biotec Inc. (Auburn,
CA), and anti-α-tubulin antibody from Oncogene Research
Products (Boston, MA). Anti-mouse IgG-TRITC conjugate
for CD44, anti-rabbit IgG-FITC conjugate for CD24 and
3-(4,5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bro-
mide (MTT), 4 ,6-Diamidino-2-phenylindole dihydrochlo-
ride (DAPI), and puromycin were purchased from Sigma-
Aldrich (St. Louise, MO).
2.2. Cell Culture. Human pancreatic carcinoma cell lines,
PANC-1, Capan-2, AsPc-1, MiaCaPa-2, and COLO357
were obtained from the American Type Culture Collection
(ATCC, Rockville, MD) and maintained in DMEM-F12
medium containing 10% FBS and 100μg/mL gentamycin.
2.3. Apoptosis and Growth Inhibition. Pancreatic cancer cell
lines were treated with 1μM 3-Cl-AHPC and AHP3 for
various indicated time. Apoptosis in cells was analyzed by
ﬂow cytometry using Annexin V-FITC binding together
with propidium iodide (PI) staining (Annexin V-FITC
apoptosis Detection Kit 1, BD Biosciences, San Diego,
CA). Data acquisition was done on a FACS Calibur ﬂow
cytometer (BD) and analyzed with CellQuest software (BD
Biosciences).3-Cl-AHPC-andAHP3-mediatedinhibitionof
cell growth were determined by 3-(4,5-dimethylthiazol-2yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. The cells
were seeded on 96-well plates at a density of 4 × 104
cells/well in a volume of 200μL culture medium. 1μM AHP3
and 3-Cl-AHPC in DMSO (ﬁnal concentration 0.1%) were
added to the cells for various times. 25μL/well of MTT
(5mg/mL) was added to the medium and incubated for
4h. After discarding the medium, MTT precipitates were
solubilized with 200μL DMSO and the plates read on a
BioTeK Synergy HT (BioTeK Instrument Inc., Vermont) at
an absorbance 570nm. All experiments were performed in
quadruplicate to determine means and standard deviations.
Cell apoptosis was assessed using acridine orange/ethidium
bromide staining as described [10]. The spheres were
stained with acridine orange/ethidium bromide staining and
immediately visualized and photographed with ﬂuorescence
microscope (OLYMPUS CKX41). For DAPI staining, the
spheres were incubated with DAPI stain for 30 minutes at
37◦C. Then spheres were visualized and photographed with
a ﬂuorescence microscope.
3. Fluorescence-Activated Cell
Sorting (FACS)ofCD44+/CD24+ Cellsand
Sphere Formation
3.1. Isolation of CD44+/CD24+Cells. Cells were grown to
70–80% conﬂuence and then trypsinised and washed with
sorting buﬀer (1 × PBS, 5% FCS). The cells were resus-
pended with 100μL sorting buﬀer and incubated with
15–20μL anti-CD133-PE, anti-EpCAM-PerCP-Cy5.5, anti-
CD24-FITC, and anti-CD44-PE primary antibodies for
30min at ice. The cells were washed and resuspended in
500μL of sorting buﬀe ra n ds o r t e du s i n gﬂ o wc y t o m e -
try FACSAria system (BD Immunocytochemistry Systems,
Franklin lakes, NJ).
3.2. Sphere Formation. The sorted CD133+, CD44+/CD24+
EpCAM+, and CD44+/CD24+ cells using ﬂow cytometry
were suspended in serum-free stem cell medium con-
taining DMEM/F12 (1:1) supplemented with B27 (Life
Technologies, Gaithersburg, MD), 20ng/mL EGF (Biomol
International, Plymouth, PA), 20ng/mL ﬁbroblast growth
factor (Biomol International, Plymouth, PA), and 100μg/mL
gentamycin. Approximately 150–200 cells per well were
seededinanultralow-attachment96-wellplate(CorningInc,
Lowell,MA).3-Cl-AHPCandAHP3wereaddedthedayafter
cells were plated or after 7 days of sphere formation. Spheres
were photographed and measured utilizing an Olympus
microscope (OLYMPUS CKX41) and Olympus microscope
digital camera with DP2-BSW software (Olympus soft
imaging solutions GmbH, Germany).Journal of Oncology 3
3.3. Western Blots. Cells were extracted with lysis buﬀer
containing 25mM Tris-Cl buﬀer (pH 8.0), 150mM NaCl,
0.2% nondiet P-40, 10% glycerol 10mM NaF, 8mM
β-glycerophosphate, 0.2mM Na3VO4, 1mM DTT, and
10μL/mL protease inhibitor cocktail (Sigma Aldrich, St.
Louise, MO), and Western blots were performed as we
previously described [11].
3.4. Immunoﬂuorescence. Approximately 150 spheres were
ﬁxedwith4%paraformaldehydein1%TritonX-100,washed
in PBS, dehydrated in methanol (25%, 50%, 75% 95%, and
100%), and then rehydrated in descending percentage of
methanol and washed in PBS. Spheroids were incubated
in 3% normal goat serum (Vector Lab, Burlingame, CA)
at 4◦C for 24h and washed in phosphate-buﬀered saline
with 0.5% Tween 20 (PBST). Then spheres were incubated
with primary antibodies anti-CD44 and anti-CD24 for 48h
at 4◦C, washed in PBST, and incubated with anti-mouse
IgG-TRITC conjugate for CD44 and CD133 and anti-
rabbit IgG-FITC conjugate for CD24 and CD326 (EpCAM)
for 24h. Spheres were mounted in 8 chambered slides
and ﬂuorescence staining analyzed. Spheres grown in 96-
well ultralow-attachment plates were incubated with DAPI
at 37◦C for 30 minutes to assess DAPI staining. For β-
catenin immunostaining, PANC-1cells were grown in eight
chambered slide and then treated with 3-Cl-AHPC for 24h.
Cells were blocked with 3% normal goat serum at 4◦Cf o r
1h and then incubated with anti-β-catenin antibody for
overnight at 4◦C. After washing with 1XPBS, cells were
incubated with anti-rabbit IgG-FITC conjugate antibody
for 2h. Cells were washed with PBS and then placed on
cover slips with prolong gold antifade reagent (Cell Signaling
Technology, Boston, MA).
3.5. Sphere Block Preparation and In Situ Sphere Cell Death
Detection. DMSO (vehicle) and 3-Cl-AHPC-treated spheres
were centrifuged at 1000rpm for 5 minutes, washed in PBS,
22% bovine serum albumin added to the spheres pellet, 95%
ethanolplacedonthespherespellet,andthepelletallowedto
harden for 30 minutes. Neutral buﬀered formalin (10%) was
addedtoﬁxthecellpelletforatleast2handthesphereswere
then placed in a labeled plastic tissue embedding cassette
containing 10% neutral buﬀered formalin overnight. The
spheres were processed in a Sakura Tissue-Tek Processor for
overnight dehydration in graded ethanol, clearing in xylene
and inﬁltration with paraﬃn. The spheres were placed in a
4μm embedding mold for ﬁnal paraﬃn embedding.
The TUNEL assay was performed using the In Situ
Cell Death Detection kit, POD (Roche-Applied-Science,
Mannheim, Germany), according to the manufacturer’s
instructions. The paraﬃn embedding spheres were deparaf-
ﬁnized and rehydrated; then tissues sections were incu-
bated with proteinase K solution (10–20μg/mL) for 30min.
Tissues were then rinsed twice in PBS and reacted with
50μL of the TUNEL reaction mixture at room tempera-
ture for 60min in a dark, humidiﬁed chamber. Sections
were again rinsed in PBS and incubated for 30min with
50μL of the Converter-POD (Roche-Applied-Science) and
followed by 3-amino-9-ethylcarbazole (AEC). Sections were
then counterstained with hematoxylin. As negative controls,
corresponding sections were treated in the same way without
terminal deoxynucleotidyl transferase.
3.6. shRNA Plasmids. Human GIPZ lentiviral shRNAmir
expression vector GFP-tagged-pGIPZ-shRNA-IGF-1R was
purchased from Open Biosystems (Thermo Scientiﬁc,
Huntsville, AL). shRNA-IGF-1R expression vectors were
stably transfected into PANC-1 cell lines using lipofectamine
2000. Stable cell lines were selected with puromycin. The
scrambled sequence shRNA-vector was used as a con-
trol. pGIPZ-shRNA expression vector clone ID V2LSH-
20147,V2LSH-131072,V3LSH-377850,V3LSH-377852,and
V3LSH-377849 inhibited IGF-1R expression more eﬀectively
in PANC-1 cells than other clones from a set of eight tested
clones.
sh-RNA-β-catenin-pSIREN-RetroQ expression vectors
were constructed according to the manufacturer’s instruc-
tions (Clontech, CA). The gene silencing target sequences
were from the coding sequence of the PubMed Accession
number NM 001904.3, and sh-RNA sequences 5 -CCATgg-
AACCAgACAgAAA-3  (catenin-KD-1) and 5 -ggATgTggA-
TACCTCCCAAg-3  (catenin-KD2) were synthesized from
Integrated DNA technology Inc. (Coralville, IA). sh-β-
cateninsequenceswereusedfordirectionalcloning5 -BamH
Ia n d3EcoR I overhang nucleotide in pSIREN-RetroQ
vector. shRNA regions in plasmid backbone were conﬁrmed
by sequencing. sh-β-catenin plasmids were used to transfect
the cell lines utilizing the lipofectamine method. The stable
cell lines were selected with puromycin, and sh-β-catenin
knockdown cell lines were grown in presence of puromycin.
Scramble sequence sh-vector was used as a control.
3.7. TCF/LEF-Luciferase Assay. In order to determine the
activation of Wnt/β-catenin signaling, the transcription fac-
tor T-cell-factor/lymphoid-enhancing-factor- (TCF/LEF)-
Luc reporter plasmid was used in PANC-1 cells. Cells were
transduced with Cignal TCF/LEF-Luc reporter lentiviral
plasmid (SA Biosciences, Frederick, MD) in presence of
polybrene (8μg/mL) for 48h and the cells were selected
with puromycin (1μg/mL). TCF/LEF cells were treated with
3-Cl-AHPC for 24h. Cells were harvested and analyzed
for TCF/LEF activity using a luciferase assay kit (Promega-
Biosciences, San Luis Obispo, CA) as followed by the
instructions of manufacturer and the activity was measured
on a BioTeK Synergy HT.
3.8. Statistical Analysis. All statistics were performed using
VassarStats web statistical software (Richard Lowry, Pough-
keepsie, NY, USA). One-way analysis of variance (ANOVA)
was performed to detect any diﬀerences between groups
of sphere control, 3-Cl-AHPC-treated spheres and AHP3-
treated spheres. If the result of the ANOVA is signiﬁcant
(P<0.01 versus control), pairwise comparisons between
the groups were made by a post hoc test (Tukey’s HSD
procedure). The signiﬁcance level was set at P<0.01 versus
control and P<0.05 versus control. Square brackets were4 Journal of Oncology
usedintheﬁgurestoindicatetreatmentsthataresigniﬁcantly
diﬀerent from the control.
4. Results
4.1. AHP3 and 3-Cl-AHPC Induction of Apoptosis in
COLO357, PANC-1, AsPc-1, Capan-2, and MiaPaCa-2 Cells.
AHP3 and 3-Cl-AHPC inhibited growth and induced apop-
tosis in Ras wild type COLO357 and Ras mutant PANC-
1, AsPc-1, Capan-2, and MiaPaCA-2 pancreatic carcinoma
cells. 1μM AHP3 or 3-Cl-AHPC resulted in the inhibition
of proliferation (Figure 1(a)). There was an 80% inhibition
COLO357 growth, 50 to 60% inhibition of PANC-1 growth,
70% inhibition of Capan-2 growth, and 60 to 70% inhibition
of MiaPaCa-2 cells at 72h by both 3-Cl-AHPC and AHP3.
AsPc-1 cells demonstrated increased resistance to both 3-Cl-
AHPC and AHP3 with only 47% and 25% growth inhibition
by 3-Cl-AHPC and AHP3, respectively, at 72h (Figure 1(a)).
Exposure of COLO357 cells to 1μM concentrations of 3-
Cl-AHPC or AHP3 resulted in apoptosis induction of 80%
of the cells at 48h. Ras mutant cell lines displayed enhanced
resistance to AHP3 and 3-Cl-AHPC-mediated apoptosis
when compared to Ras wild type cell line COLO357
(Figure 1(b)). 3-Cl-AHPC and AHP3 exposure resulted
in 22% apoptosis at 24h and 50% and 48% apoptosis,
respectively, at 48h in PANC 1 cells (Figure 1(b)). Similar
results were noted with Capan-2 cells with 40 and 50%
apoptosis at 24h and 48h, respectively (Figure 1(b)). 3-
Cl-AHPC and AHP3 exposure resulted in 35% and 40%
apoptosis of AsPC-1 cells at 48h, respectively (Figure 1(b)).
Control MiaPaCa-2 cells showed 60% Annexin V-FITC
positivity; however, these cells were not apoptotic by any
other criteria and grew normally in culture. Therefore,
acridine orange/ethidium bromide staining was utilized as
we have previously described to assess DNA fragmentation
and apoptosis [6]. Exposure to 3-Cl-AHPC and AHP3
resulted in 30% apoptosis at 48h and 60% induction of
apoptosis at 72h and 96h.
Numerous studies have supported the concept that
the stem cell population is responsible for the persistent
resistance of cancer cells to chemotherapy as well as their
metastatic behavior [12–15]. Previous studies have shown
that pancreatic cancers and pancreatic cancer cell lines
contain a small segment of cell population characterized
by expression of CD133 or CD44/CD24/EpCAM positivity
and which can be utilized to identify this cancer stem cell
population [16–19]. While there appears to be signiﬁcant
overlap between CD133 positive and CD44+/CD24+ cells,
this overlap appears to vary between diﬀerent tumor samples
with only 10 to 40% of the CD44+/CD24+ cells expressing
CD133 [4]. The intriguing observation that both CD133
positive and CD44+/CD24+ cells have been found to be
tumor initiating cells and possess many of the characteristics
of cancer stem cells suggests that heterogeneity exists in the
pancreatic cancer stem cell population.
Pancreatic cancer stem cells have been characterized
by stem cell markers CD133+ and CD44+/CD24+/EpCAM+
(epithelial adhesion molecule)/ESA (epithelial speciﬁc anti-
gen) [3, 4, 20]. To investigate the eﬃciency of ARR in
inhibiting the growth of cancer stem cells, we examined
the inhibition of sphere formation in CD44+/CD24+/
EpCAM+ and CD133+ cancer stem cells. PANC-1 cells were
sorted by ﬂow cytometry to obtain CD133+ and CD44+/
CD24+/EpCAM+expressing cells and cells were allowed to
form spheres in the DMEM/F12-B27 medium for 7 days. 3-
Cl-AHPC and AHP3 exposure completely inhibited sphere
formation as well as addition of 3-Cl-AHPC or AHP3 on
day7aftersphereformationresultedinsigniﬁcantinhibition
of sphere growth of CD133+ and CD44+/CD24+/EpCAM+
PANC-1 stem cells (Figures 2(a)–2(d)). Sphere formation in
nonadherent conditions is a unique property of cancer stem
cells in general [16]. Studies have demonstrated resistance of
pancreatic stem cells to chemotherapy agents including gem-
citabine [3, 12, 15]. We assessed the ability of ARRs to inhibit
sphere formation from the sorted CD44+/CD24+ stem-like
cells in B27 medium. 3-Cl-AHPC or AHP3 addition at
the time of PANC-1 seeding in B27 medium completely
inhibited sphere formation by the cells at day 7 and day 14
(Figure 2(e) and see Figure S1A in Supplementary Material
available online at doi: 10.1155/2012/796729.), while addi-
tion of 3-Cl-AHPC or AHP3 on day 7 after sphere formation
resulted in a 70% inhibition of sphere formation as well
as degradation of the sphere cells at day 14 (Figure 2(f)
and Supplementary Figure S1B). In order to determine
the expression of CD44, CD24, EpCAM, and CD133 in
CD44+/CD24+ sphere cells, we stained the spheres with ﬂu-
orescent antibody for TRITC-conjugate-CD44 and CD133,
and FITC-conjugate-CD24 and EpCAM. Utilizing confocal
microscopy overlay, we conﬁrmed that the PANC-1 spheres
consisted of CD44+/CD24+ cells (Supplementary Figure
S2A). These cells expressed not only CD44+/CD24+ but also
CD133 as well as EpCAM (Supplementary Figure S2B).
3-Cl-AHPC or AHP3 addition to the CD44+/CD24+
MiaPaCa-2 and Capan-2 cells at the time of seeding in
the B27 medium also totally inhibited spheres formation
(Figures 3(a) and 3(c)). Similarly, 3-Cl-AHPC or AHP3
exposure at day 7 after sphere formation taken place resulted
in a 70% and 50% inhibition of sphere size in the MiaPaCa-2
and Capan-2 cells, respectively (Figures 3(b) and 3(d)).
The 3-Cl-AHPC dose required to inhibit sphere forma-
tion by the PANC-1 cells was determined. The addition
of 0.25, 0.5, or 1μM 3-Cl-AHPC to PANC-1 cells at the
time of seeding in B27 medium resulted in more than a
50% inhibition of sphere formation (Figure 4(a)); 0.1μM
did not inhibit sphere formation (Figure 4(a)). 3-Cl-AHPC
concentrations of 0.5 and 1μM were required to reduce
PANC-1 sphere size greater than 80% when added at
day 7 after sphere formation (Figure 4(b)), resulting in
disaggregation of the sphere and apoptosis induction of the
cells, as documented by DNA fragmentation demonstrated
by acridine orange/ethidium bromide, DAPI staining, and
positive TUNEL staining of the spheres (Figures 4(c), 4(d),
and 4(e)).
Further evidence of AHP3 and 3-Cl-AHPC-mediated
apoptosis of CD44+/CD24+ PANC-1 cells was demonstrated
by Annexin V-FITC and PI staining. 3-Cl-AHPC and AHP3
exposure of PANC-1 cells resulted in 80% apoptosis after
96h treatment (Figure 5(a) and Supplementary Figure S2C).Journal of Oncology 5
0
0.2
0.4
0.6
0.8
1
1.2
1.4
I
n
h
i
b
i
t
i
o
n
 
o
f
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
I
n
h
i
b
i
t
i
o
n
 
o
f
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
I
n
h
i
b
i
t
i
o
n
 
o
f
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
I
n
h
i
b
i
t
i
o
n
 
o
f
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
I
n
h
i
b
i
t
i
o
n
 
o
f
 
p
r
o
l
i
f
e
r
a
t
i
o
n
 
0
0.5
1
1.5
2
2.5
3
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
0.5
1
1.5
2
2.5
0
0.5
1
1.5
2
MiaPaCa-2
Control
3-Cl-AHPC
AHP3
COLO357
24 h 48 h 72 h 24 h 48 h 72 h 24 h 48 h 72 h
24 h 48 h 72 h 24 h 48 h 72 h
Capan-2
AsPc-1
PANC-1
(a)
0
20
40
60
80
100
Control 24 h 48 h
0
10
20
30
40
50
60
Control  24 h 48 h
0
10
20
30
40
50
60
70
Control  24 h 48 h
0
10
20
30
40
50
60
70
24 h 48 h 72 h
0
5
10
15
20
25
30
35
40
Control 24 h 48 h
3-Cl-AHPC
AHP3 Control
3-Cl-AHPC
AHP3
COLO357
Capan-2 AsPc-1
PANC-1
A
p
o
p
t
o
s
i
s
 
(
%
)
(
a
n
n
e
x
i
n
V
-
F
I
T
C
 
a
n
d
 
P
I
)
A
p
o
p
t
o
s
i
s
 
(
%
)
(
a
n
n
e
x
i
n
V
-
F
I
T
C
 
a
n
d
 
P
I
)
A
p
o
p
t
o
s
i
s
 
(
%
)
(
a
n
n
e
x
i
n
 
V
-
F
I
T
C
 
a
n
d
 
P
I
)
A
p
o
p
t
o
s
i
s
 
(
%
)
(
a
n
n
e
x
i
n
 
V
-
F
I
T
C
 
a
n
d
 
P
I
)
MiaPaCa-2
D
N
A
 
f
r
a
g
m
e
n
t
a
t
i
o
n
 
(
%
)
(b)
Figure 1: 3-Cl-AHPC- and AHP3-mediated proliferation inhibition and apoptosis induction in pancreatic cancer cell lines. The cells were
e x p o s e dt o1μM 3-Cl-AHPC or AHP3 for various times. (a) Proliferation inhibition was evaluated by MTT assay as described Section 2
and expressed as absorbance (OD) measured at 570nm. The error bars represent the mean of three separate determinations ± the standard
deviation (SD). (b) Induction of apoptosis in pancreatic cancer cells by 3-Cl-AHPC and AHP3. Cells were seeded at 1 × 104 cells/mL and
g r o w nf o r2 4ha n dt h e ne x p o s e dt o1μM AHP3 or 3-Cl-AHPC for indicated times. Induction of apoptosis and cell death was assessed
using Annexin V-FITC labeling with propidium iodide (PI) staining in COLO357, PANC-1, Capan-2 AsPc-1, or acridine orange/ethidium
bromide staining in MiaPaCa-2. The error bars represent the mean of three separate determinations ± the standard deviation (SD). All
treated samples are signiﬁcantly diﬀerent from vehicle control.
We sorted the 3-Cl-AHPC- and AHP3-treated PANC-1
cells for CD44+/CD24+cells and assessed the percentage of
these cells that were apoptotic by determining Annexin V-
FITC positive staining. Flow cytometry analysis showed that
CD44+/CD24+-gated early apoptotic (Annexin V-FITC +
and PI−) cells were 36% and 40% for the 3-Cl-AHPC-
and AHP3-treated cells, respectively (Figure 5(b) and Sup-
plementary Figure S2D, upper panel). Late apoptotic cells
(Annexin V-FITC + and PI +) were 51% and 57% for the 3-
Cl-AHPC- and AHP3-treated cells, respectively (Figure 5(b)6 Journal of Oncology
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Figure 2: 3-Cl-AHPC-mediated inhibition and degradation of pancreatic cancer stem cells spheres of CD133+,C D 4 4 +/CD24+/EpCAM+,
and stem-like spheres of CD44+/CD24+ PANC-1 cells. ((a), (b) and (c), (d)) 3-Cl-AHPC and AHP3 exposure resulted in inhibition of
CD44+/CD24+/EpCAM+ and CD133+cells growth and sphere formation and degradation of the derived spheres. ((e), (f)) AHP3 and 3-Cl-
AHPC inhibited sphere formation and inhibition of growth and degradation of the CD44+/CD24+-derived spheres. For sphere formation,
the CD44+/CD24+/EpCAM+, CD133+,a n dC D 4 4 +/CD24+ cells were sorted by ﬂow cytometry and approximately 200–300 cells were seeded
with B27 containing DMEM/F12 medium in 96-well low attachment plates and 1μM 3-Cl-AHPC or AHP3 added either the day after
seeding or 7 days following sphere formation. The sizes of spheres were photographed and measured on a 100μm scale and magniﬁcation
400X using Olympus ﬂuorescence microscope digital camera software and DP2-BSW software. The error bars represent the mean of 15
sphere determinations ± the standard deviation. ∗∗ was signiﬁcantly diﬀerent in comparison to control spheres. Data were analyzed by
ANOVA, Tukey HSD test for multiple comparisons. ∗∗P<0.01 versus control.
and Supplementary Figure S2D, bottom panel). Thus, a total
of 80% of the CD44+/CD24+ PANC-1 cell population were
apoptotic after 96h exposure to either 3-Cl-AHPC or AHP3
(Figure 5(c) and Supplementary Figure S2E).
The ability of AHP3 and 3-Cl-AHPC to induce apopto-
sis in CD44−/CD24−, CD44+/CD24−, CD44−/CD24+,a n d
CD44+/CD24+ cells was also examined. These cell popula-
tions were isolated from PANC-1 cells and treated with 3-
Cl-AHPC. The addition of 1μM 3-Cl-AHPC to the various
cell populations resulted in the growth inhibition and the
induction of apoptosis as indicated by DNA fragmentation
(Supplementary Figures S3 and S4).Journal of Oncology 7
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Figure 3: 3-Cl-AHPC- (1μM) and AHP3- (1μM) mediated inhibition of CD44+/CD24+ stem-like cell sphere formation and degradation
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∗∗ Was signiﬁcantly diﬀerent in comparison to control spheres. Data were analyzed by ANOVA, Tukey HSD test for multiple comparisons.
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4.2. 3-Cl-AHPC Decreases Expression of IGF-1R, Cyclin D1,
and β-Catenin in Pancreatic Cancer Cells. 3-Cl-AHPC and
AHP3 exposure on the expression of cyclin D1, β-catenin,
andIGF-1Rinthepancreaticcancercellswasassessed.Cyclin
D1 is an important regulatory protein required in cell cycle
progression, and overexpression has been associated with
a poor prognosis in patients with pancreatic cancer [21].
Inhibition of cyclin D1 expression has been found to inhibit
pancreatic cancer growth [21]. Abnormal expression of β-
catenin was found to be associated with the development of
metastatic pancreatic cancer as well as the upregulation of
cyclin D1, c-Myc, and matrix-metalloproteinase-7 [22, 23].
IGF-1R and IGF-1 are overexpressed in human pancreatic
tumors. IGF-1R signaling regulates proliferation, invasion,
and angiogenic growth factor expression by pancreatic
cancer cells [24–26].
3-Cl-AHPC exposure on pancreatic cancer cells
decreased expression of IGF-1R, cyclin D1, and β-catenin
prior to the inhibition of proliferation and the induction
of apoptosis (Figures 5(d) and 5(e)). There was a 82%,
90%, 68%, and 31% inhibition of IGF-1R expression
in the PANC-1, Capan-2, MiaPaCa-2, and AsPc-1cells,
respectively, at 48h following 3-Cl-AHPC exposure. 3-Cl-
AHPC-mediated inhibition of cyclin D1 expression was
80%, 85%, 52%, and 69% in PANC-1, Capan-2, MiaPaCa-2,
and AsPc-1cells, respectively, at 48h (Figures 5(d) and
5(e)), and Supplementary Figure S5A). The addition of
3-Cl-AHPC to the PANC-1, Capan-2, MiaPaCa-2, and
AsPc-1 cells resulted in a decrease of 65%, 66%, 22%,
and 43%, respectively, in β-catenin expression (Figures
5(a) and 5(e) and Supplementary Figure S5A). Similarly,
3-Cl-AHPC exposure in COLO357 cells decreased IGF-1R
(43%), cyclin D1 (93%), and β-catenin (85%), respectively,
at 24h following 3-Cl-AHPC exposure (Figure 5(e) and
Supplementary Figure S5A). AHP3 exposure in PANC-1
cells also decreased IGF-1R, cyclin D1, and β-catenin
(Supplementary Figure S5B). These results suggest that
decrease of IGF-1R, cyclin D1, and β-catenin reﬂects a
phenomenon general to ARR-mediated apoptosis induction
in pancreatic cancer cells.
A 58%, 95%, and 50% decrease in IGF-1R, cyclin
D, and β-catenin expression was noted in the PANC-1
CD44+/CD24+spheres following exposure to 3-Cl-AHPC,
respectively, followed by apoptosis (Figure 6(a) and Supple-
mentary Figure S5C). Sphere apoptosis was supported by the
observation of cleavage of caspase 3 following 3-Cl-AHPC
exposure on PANC-1 sphere cells (Figure 6(a)).8 Journal of Oncology
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Figure 4: Dose-response eﬀect of 3-Cl-AHPC on CD44+/CD24+ cells sphere formation and apoptosis in PANC-1 sphere cells. (a) Addition
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assay. CD44+/CD24+ spheres were treated with 1.0μM ARRs for 7 days (7D) after sphere formation. Details of slides preparation,
visualization, antibodies utilized, and TUNNEL assay methodologies were as described in Section 2.
Self-renewal of CSCs has been shown to be regulated
by the Wnt/β catenin, Hedgehog, and Notch signaling
pathways [27, 28]. Lee et al. [4] found that expression of
sonic hedgehog transcripts was increased by 46-fold in the
CD44/CD24/EpCAM positive cells derived from pancreatic
cancer cells while there was only a 4-fold increase in
the CD44/CD24/EpCAM negative population. 3-Cl-AHPC
downregulated the GLI1, GLI2, and Ptch1 mRNA expression
in the hedgehog pathway (Figure 6(b)) and decreased the
basal activated cleaved Notch-1 (Val 1744) expression in
PANC-1cellsbutnotinCD44+/CD24+spheres(Figure 6(a)).
In order to examine the biological relevance of
decreased IGF-1R expression, IGF-1R expression was inhib-
ited in PANC-1 cells utilizing pGIPZ-lentiviral-shRNA-
IGF-1R expression vector (Figure 6(d)). Decreased IGF-1R
expression inhibited the growth of the PANC-1 pancre-
atic cancer cells and increased the 3-Cl-AHPC-mediated
inhibition of CD44+/CD24+sphere size (Figure 6(c) and
Supplementary Figure S6A). Decreased IGF-1R expression
in IGF1R-KD1 and IGF1R-KD2 cells signiﬁcantly inhibited
sphere formation by the PANC-1 CD44+/CD24+ cells and
enhanced ARR induction of apoptosis in the IGF-1R knock-
down PANC-1 cells (Figures 6(c) and 6(d)).
Wnt/β-catenin signaling pathway leads to dephosphory-
lation, stabilization, and nuclear translocation of β-catenin.
Nuclear β-catenin forms a complex with TCF/LEF family
transcription factors and acts as a coactivator to express
target genes in canonical Wnt signaling pathway such as
CCND1 and MYC [27, 29]. We found that exposure to
the 3-Cl-AHPC resulted in a decrease in nuclear β-catenin
(Figures 7(a) and 7(b)) and also signiﬁcantly decreased
the TCF/LEF- transcriptional activity in wild-type cells as
well as CD44+/CD24+ stably transfected TCF/LEF-sorted
cells (Figure 7(c)). 3-Cl-AHPC decreased the expressionJournal of Oncology 9
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Figure 5: 3-Cl-AHPC and AHP induced apoptosis in PANC-1 CD44+/CD24+ cells and 3-Cl-AHPC decreased expression of IGF-1R, cyclin
D1,andβ-catenininpancreaticcancercells.(a)Percentageoftotalapoptoticcells.(b)PercentageofCD44+/CD24+ cellsintheearly(Annexin
V-FITC positive and PI negative) or late (Annexin V-FITC positive and PI positive) apoptotic cell populations. (c) Percentage of total
CD44+/CD24+ apoptotic cells (Annexin V-FITC positive and PI positive). Cells were treated with 1.0μM 3-Cl-AHPC and AHP3 for 96h.
Antibody-conjugated markers CD44-APC-Cy7, CD24-APC, Annexin V-FITC, and PI were used to detect apoptotic and CD44+/CD24+ cells
from the same samples. The error bars represent the mean of three separate determinations ± the standard deviation. ((d), (e)) IGF-1R,
cyclin D1, and β-catenin expression decreased following 3-Cl-AHPC exposure in pancreatic cancer cells.
of Wnt/β-catenin pathway responsive cyclin D1 and c-
Myc in the PANC-1 cells within 24h (Figures 5(d) and
7(d)). Inhibition of β-catenin expression using sh-RNA β-
catenin signiﬁcantly inhibited cell growth and enhanced
3-Cl-AHPC-mediated induction of apoptosis (Figures 7(e)
and 7(f) and Supplementary Figure S6C). Thus, β-catenin
expression and its general antiapoptotic eﬀect mediated
through a number of the β-catenin target genes inhibit ARR
apoptosis induction.
5. Discussion
ARRs at physiologically achievable concentrations induce
a p o p t o s i so fan u m b e ro fp a n c r e a t i cc a n c e rc e l ll i n e sa sw e l l
as inhibit sphere formation by the CD44+/CD24+ stem-like
cell population derived from the pancreatic cancer cell lines.
Although ARRs were initially synthesized to demonstrate
selectivity in the activation of retinoid nuclear receptor
(RAR)subtypes,theyhavebeenshowntoinhibit growthand10 Journal of Oncology
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Figure 6: 3-Cl-AHPC decreased expression of IGF-1R, cyclin D1, β-catenin, and cleaved Notch-1 and increased levels of cleaved-caspase-3
in CD44+/CD24+spheres. (a) IGF-1R, cyclin D1, and β-catenin expression decreased cleaved-caspase-3 increased with no change in Notch-1
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Figure 7: 3-Cl-AHPC mediated inhibition of the activation of TCF/LEF in Wnt/β-catenin pathway and decreased of β-catenin
nuclear localization. (a) 3-Cl-AHPC decreased nuclear β-catenin as indicated by Western blot using nuclear extracts and densitometric
quantiﬁcation. (b) Nuclear β-catenin in control- (i) and 3-Cl-AHPC- (ii) treated PANC-1 cells using confocal ﬂuorescent microscope
(magniﬁcation 40X). Cells were grown in eight chambered slides and then treated with 3-Cl-AHPC for 24h. Slide was prepared as described
in Section 2. DAPI was used for nuclear staining for 1min and mounted the slide with prolong gold antifade kit. (c) 3-Cl-AHPC inhibited
TCF/LEF activity in Wnt/β-catenin signaling in stably transfected Cignal TCF/LEF-Luc reporter PANC-1 cell lines and 50mM LiCl was used
as a positive control. For CD44/CD24 cells, TCF/LEF stably transfected cells were sorted by ﬂow cytometry and followed the procedure same
as wild type (Wt) stable cell line. Luciferase promoter activity values are expressed as fold using a total protein concentration for internal
normalization. The error bars represent the mean of three separate determinations ± the standard deviation (SD). (d) 3-Cl-AHPC decreased
Wnt/β-catenin signaling responsive c-Myc protein. ((e) and (f)) Knock down of β-catenin inhibited cell proliferations and enhanced more
apoptosis in sh-β-catenin knockdown (KD) PANC-1 cell lines. Proliferation inhibition was evaluated after 72h of seeding the cells by MTT
assay and expressed as absorbance measured at 570nm. The error bars represent the mean of three separate determinations ± the standard
deviation (SD). ∗∗ (<0.01) was signiﬁcantly diﬀerent in comparison between sh-vector and Catenin-KDl/Catenin-KD2 and also between
sh-vector and catenin-KD1/Catenin-KD2 treated with 3-Cl-AHPC, respectively.12 Journal of Oncology
induce apoptosis in diﬀerent malignant cell types indepen-
dent of RAR and retinoid x receptor (RXR) activation and
function [30–34]. We found that Ras wild type and mutant
pancreatic cancer cell lines COLO357, PANC-1, Capan-2,
AsPc-1 cells, and MiaPaCa-2 display signiﬁcant sensitivity
to AHP3- and 3-Cl-AHPC-mediated growth inhibition and
apoptosis induction.
Numerous mechanisms have been suggested through
which ARR induces apoptosis in these cells [29–33]. The
ability of the ARRs to enhance or inhibit the expression
of a number of genes and proteins has been demonstrated
[30–35]. We have found that both 3-Cl-AHPC and AHP3
signiﬁcantly decreased IGF-1R and β-catenin expression and
thatthedecreasedexpressionofIGF-1Randβ-catenininhib-
ited the growth and enhanced apoptosis of the pancreatic
cancer cells suggesting that decreased IGF-1R and β-catenin
expression potentiates ARR-mediated apoptosis.
Recentstudies havedemonstratedthatmalignant tumors
are heterogeneous in composition with the stem cell pop-
ulation representing those cells that display resistance to
chemotherapy and have greater metastatic potential [3, 29,
36]. Huang et al. utilized CD44/CD24/EpCAM positivity to
identify the stem cell population in the PANC-1 pancreatic
cell line [37]. They found that this stem cell population—
which represented 2.1–3.5% of the total cell population—
displayed a slower growth rate than CD44/CD24 negative
cells and when injected rapidly formed large tumors in nude
mice at week 4 while CD44/CD24 negative cells did not
form tumors. Simeone similarly used CD24/CD44/EpCAM
to identify a pancreatic CSC population that displayed the
a b i l i t yt of o r mt u m o rc e l ls p h e r e sa sw e l la se n h a n c e dt u m o r
formation in nude mice [38]. In contrast, Hermann and
colleagues utilized CD133 positivity to select a pancreatic
cancer stem cell population from freshly isolated patient-
derived tumors [3]. These CD133 positive cancer stem cells
represented a heterogeneous population of tumor-initiating
cells and only 500 of these cells were required to form
orthotropic tumors in athymic mice [3]. Thus, markers
purportedly in cancer stem cells appear not to detect all
cancer stem cells in a particular tumor. We found how-
ever that spheres generated from CD44+/CD24+expressing
pancreatic cancer cells also expressed CD133 as well as
EpCAM. More recently, other markers, such as Aldehyde
dehydrogenase (ALDH), have been found to be associated
with the pancreatic cancer stem cell population [39].
IGF-1 and its receptor IGF-1R play a major role in
proliferation, invasive potential, and metastatic behavior of
pancreatic cancer cells [24–26]. IGF-1 exposure decreased
phosphorylation and inactivation of PTEN and activation of
P I 3 K ,A K T ,a n dt h eN F - κB pathway in a number of pancre-
atic cancer cell lines resulting in their enhanced proliferation
andinvasiveness[24].Otherinvestigatorshavedemonstrated
that IGF-1R regulated hypoxia-inducible factor-1α, vascular
endothelial growth factor, and angiogenesis through an
autocrineloopinpancreaticcancercells[25].Furtherstudies
have documented that IGF-1/IGF-1R-mediated enhanced
pancreatic carcinoma proliferation and invasiveness requires
an interaction between IGF-1R and the hepatocyte growth
receptor c-Met [26]. Dallas et al. have recently demonstrated
enhanced IGF1R expression as well cancer stem cell markers
in colon cancer cells displaying chemotherapy resistance
[40]. In addition, these cells displayed greater sensitivity in
terms of inhibition of growth following exposure to IGF-
1R inhibitory antibody [40]. The addition of either ARR to
the PANC-1, Capan-2, or MiaPaCa-2 cells downregulated
expression of IGF-1R, cyclin D1, and β-catenin; decreased
expression of these important proteins in the adherent
cells, and the CD44+/CD24+ stem-like cells occurred prior
to the onset of inhibition of cellular proliferation and
the induction of apoptosis. We found that IGF-1R was
signiﬁcantly expressed in the pancreatic cancer sphere cells
and its expression was markedly inhibited by exposure to 3-
Cl-AHPC. The importance of IGF-1R in the proliferation
of the pancreatic cancer cells, as well as their resistance
to apoptosis, was documented by the observation that
IGF-1R knockdown inhibited proliferation, enhanced 3-Cl-
AHPC-mediated apoptosis, and inhibited sphere formation
in PANC-1 cells.
Several investigators have demonstrated that β-catenin
is essential for normal pancreatic development through
the canonical Wnt signaling pathway but this pathway is
downregulated in adult pancreas [41, 42]. Mutations in β-
catenin or abnormal canonical Wnt signaling activity have
been documented in pancreatic cancer [43–45]. Heiser et
al. [45] have demonstrated that enhanced Wnt/β-catenin
signaling in itself can induce pancreatic tumorgenesis and
that activation of other oncogenes in the presence of
enhanced Wnt/β-catenin signaling induces distinct pancre-
atic tumor formation. Addition of 3-Cl-AHPC downreg-
ulated β-catenin expression in pancreatic cancer cells and
inhibited Wnt/β-catenin activation of transcription factor
TCF/LEF and also downregulated Wnt/β-catenin pathway
responsive genes cyclin D1 and c-Myc in PANC-1 cells.
We found that β-catenin was signiﬁcantly expressed in
the pancreatic cancer sphere cells and that 3-Cl-AHPC
inhibited this expression. 3-Cl-AHPC also downregulated
GLI1, GLI2, and Ptch1 mRNA expression in the hedgehog
pathway. ARR-mediated inhibitory eﬀect on the self-renewal
pathways, hedgehog and Wnt/β-catenin, may contribute to
the inhibition of pancreatic cancer stem-like cell spheres.
AHP3 and 3-Cl-AHPC may have a potential therapeutic role
in the treatment of pancreatic cancer and further studies will
delineate underlying mechanisms of inhibition for cancer
stem cell self-renewal pathways.
6. Conclusions
Pancreatic cancer is resistant to chemotherapy and is a
leading cause of cancer death. The adamantyl-substituted
retinoid-related compounds 3-Cl-AHPC and AHP3 inhibit
both pancreatic cancer and pancreatic stem-like cancer cells
growth at physiologically achievable concentration. Inhibi-
tion of IGF-1R and β-catenin potentiates ARR-mediated
growth inhibition and induction of apoptosis. 3-Cl-AHPC
and AHP3 apoptosis induction in pancreatic cancer and
pancreatic stem-like cancer cells suggested a potential ther-
apeutic agent for pancreatic cancer.Journal of Oncology 13
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